SAB Biotherapeutics, Inc.
SABS
$3.72
$0.082.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -92.42% | -95.87% | -85.48% | -40.94% | -63.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -92.42% | -95.87% | -85.48% | -40.94% | -63.06% |
| Cost of Revenue | -55.33% | -62.15% | 12.36% | 39.89% | 2.03% |
| Gross Profit | 52.25% | 57.58% | -26.90% | -52.56% | -19.49% |
| SG&A Expenses | -54.07% | -53.33% | -48.22% | -42.09% | 121.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.73% | -13.65% | -4.47% | 9.72% | 71.03% |
| Operating Income | 16.58% | 8.66% | -0.54% | -12.70% | -91.33% |
| Income Before Tax | 141.13% | 8.10% | 14.02% | 19.17% | -67.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 141.13% | 8.10% | 14.02% | 19.17% | -67.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 141.13% | 8.10% | 14.02% | 19.17% | -67.46% |
| EBIT | 16.58% | 8.66% | -0.54% | -12.70% | -91.33% |
| EBITDA | 14.39% | 5.64% | -3.89% | -11.03% | -101.49% |
| EPS Basic | 90.82% | 62.14% | 40.99% | 48.73% | -5.16% |
| Normalized Basic EPS | 123.77% | 29.82% | 40.94% | 48.69% | -5.07% |
| EPS Diluted | 78.60% | 62.10% | 40.95% | 48.70% | -5.21% |
| Normalized Diluted EPS | 60.71% | 29.82% | 40.94% | 48.69% | -5.07% |
| Average Basic Shares Outstanding | 11.66% | 21.78% | 41.13% | 67.76% | 74.15% |
| Average Diluted Shares Outstanding | 206.36% | 21.78% | 41.13% | 67.76% | 74.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |